Late antibody‐mediated rejection (ABMR) is a cardinal cause of kidney allograft failure,
manifesting as a continuous and, in contrast with early rejection, often clinically silent …

Currently, kidney transplantation is the best treatment option for kidney failure for a majority
of eligible patients. It is associated with a better quality of life and reduced mortality as …

Background. Antibody-mediated rejection (AMR) is a leading cause of morbidity and
mortality after kidney transplantation. Early diagnosis and treatment of subclinical AMR …

The ability to personalize management for a given kidney transplant recipient and identify
treatments that will improve their long-term outcome remains a critical unmet need. Earlier …

BACKGROUND The histopathological findings on the failing kidney allograft in the modern
era is not well studied. In this study, we present our experience working with kidney …

Background. Limited information exists about outcomes of HLA donor-specific antibody
(DSA) negative (DSA−) microvascular inflammation (MVI). Methods. We report our …

Introduction Donor-specific antibodies (DSAs) are considered an important risk factor for
graft injury and failure. However, there is limited information on long-term outcomes for …

Chronic rejection is the primary cause of late allograft failure, however, the current
treatments for chronic rejection have not yielded desirable therapeutic effects. B cell …

Simple Summary The most common cause of late allograft failure is chronic active antibody-
mediated rejection (ABMR), but no effective therapy is available. Different …

Therapeutic apheresis (TA) plays a significant role in various aspects of renal
transplantation. It has been a necessary preconditioning component in ABO incompatible …